4.6 Article

Proteoglycan 4 Modulates Osteogenic Smooth Muscle Cell Differentiation during Vascular Remodeling and Intimal Calcification

Journal

CELLS
Volume 10, Issue 6, Pages -

Publisher

MDPI
DOI: 10.3390/cells10061276

Keywords

Proteoglycan 4; smooth muscle cells; atherosclerosis; extracellular matrix; vascular remodeling; calcification

Categories

Funding

  1. European Union [722609]
  2. Swedish Heart and Lung Foundation [20180036, 20170584, 20180244, 201602877, 20180247]
  3. Swedish Research Council [2017-01070, 2019-02027]
  4. Stockholm County Council
  5. Swedish Society for Medical Research
  6. Swen and Ebba Hagberg's Foundation
  7. Tore Nilsson's Foundation
  8. Magnus Bergvall's Foundation
  9. Dutch Thrombosis Society [2014.02]
  10. NWO ZonMw [MKMD 40-42600-98-13007]
  11. Karolinska Institute Foundation
  12. Swedish Heart-Lung Foundation [20180036] Funding Source: Swedish Heart-Lung Foundation
  13. Swedish Research Council [2017-01070] Funding Source: Swedish Research Council

Ask authors/readers for more resources

Calcification is a key feature of late-stage atherosclerosis, and recent research has shown that the expression of PRG4 is correlated with vascular remodeling and intimal calcification. Experimental models suggest that PRG4 plays a role in SMC function and osteogenic phenotype, impacting atherosclerotic plaque stability. Further investigations are needed to better understand the mechanisms behind PRG4's effects on calcification and SMC behavior.
Calcification is a prominent feature of late-stage atherosclerosis, but the mechanisms driving this process are unclear. Using a biobank of carotid endarterectomies, we recently showed that Proteoglycan 4 (PRG4) is a key molecular signature of calcified plaques, expressed in smooth muscle cell (SMC) rich regions. Here, we aimed to unravel the PRG4 role in vascular remodeling and intimal calcification. PRG4 expression in human carotid endarterectomies correlated with calcification assessed by preoperative computed tomographies. PRG4 localized to SMCs in early intimal thickening, while in advanced lesions it was found in the extracellular matrix, surrounding macro-calcifications. In experimental models, Prg4 was upregulated in SMCs from partially ligated ApoE(-/-) mice and rat carotid intimal hyperplasia, correlating with osteogenic markers and TGFb1. Furthermore, PRG4 was enriched in cells positive for chondrogenic marker SOX9 and around plaque calcifications in ApoE(-/-) mice on warfarin. In vitro, PRG4 was induced in SMCs by IFNg, TGFb1 and calcifying medium, while SMC markers were repressed under calcifying conditions. Silencing experiments showed that PRG4 expression was driven by transcription factors SMAD3 and SOX9. Functionally, the addition of recombinant human PRG4 increased ectopic SMC calcification, while arresting cell migration and proliferation. Mechanistically, it suppressed endogenous PRG4, SMAD3 and SOX9, and restored SMC markers' expression. PRG4 modulates SMC function and osteogenic phenotype during intimal remodeling and macro-calcification in response to TGFb1 signaling, SMAD3 and SOX9 activation. The effects of PRG4 on SMC phenotype and calcification suggest its role in atherosclerotic plaque stability, warranting further investigations.

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.6
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

No Data Available
No Data Available